Video Buzz v1

Related Norepinephrine News

Sepracor Clinical Depressive Disorder Drug Misses Primary Endpoint In ... - RTT News

(RTTNews) - Wednesday, Sepracor Inc. (SEPR: News ) said its Phase II clinical trail to evaluate efficacy and safety of SEP-225289 for treatment of major depressive disorder did not meet the primary end-point. The Marlborough, Massachusetts-based ...

UPDATE 1-Two Sepracor drugs suffer setback, shares tumble - Reuters

NEW YORK, July 1 (Reuters) - U.S. biotechnology company Sepracor Inc ( SEPR.O ) on Wednesday suffered a double setback as its experimental depression drug failed a mid-stage study and U.S. regulators halted two pediatric studies of its blockbuster ...

Sepracor Provides Update On Clinical Trials For SEP-225289 And LUNESTA ... - Medical News Today

Sepracor Inc. (Nasdaq: SEPR) announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP-225289 for the treatment of Major Depressive Disorder ...

Treating pain improves cognition in the elderly - Philippine Star Online

It is not always appreciated that pain can increase anxiety, depression, and cognitive impairment. Pain is a comorbid condition too often overlooked in the setting of geriatric psychiatry, despite the potential for better mental health outcomes when ...

Sepracor tumbles as drugs suffer setback - Boston Globe

NEW YORK - Sepracor Inc. , a Marlborough, Mass., biotechnology company, yesterday suffered a double setback as its experimental depression drug failed a midstage study and US regulators halted two pediatric studies of its blockbuster Lunesta insomnia ...

Norepinephrine Podcasts

Do you prefer to listen to your norepinephrine gossip? Check out Podzy Podcast Directory > Norepinephrine.

Norepinephrine Products

Looking for norepinephrine related products, then look no further. Try our new Norepinephrine Shop.